These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3886025)

  • 1. High-dose naloxone administration in chronic schizophrenia.
    Cohen MR; Pickar D; Cohen RM
    Biol Psychiatry; 1985 May; 20(5):573-5. PubMed ID: 3886025
    [No Abstract]   [Full Text] [Related]  

  • 2. Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects.
    Kleinman JE; Weinberger DR; Rogol A; Shiling DJ; Mendelson WB; Davis GC; Bunney WE; Wyatt RJ
    Psychiatry Res; 1982 Aug; 7(1):1-7. PubMed ID: 6127744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone-induced reduction of schizophrenic symptoms.
    Jørgensen HA; Cappelen C
    Acta Psychiatr Scand; 1982 May; 65(5):370-4. PubMed ID: 6126068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naloxone treatment for five days ineffective in schizophrenia. Neuroendocrine actions of the opiate antagonist.
    Naber D; Münch U; Wissmann J; Grosse R; Ritt R; Welter D
    Acta Psychiatr Scand; 1983 Apr; 67(4):265-71. PubMed ID: 6305111
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study.
    Pickar D; Vartanian F; Bunney WE; Maier HP; Gastpar MT; Prakash R; Sethi BB; Lideman R; Belyaev BS; Tsutsulkovskaja MV; Jungkunz G; Nedopil N; Verhoeven W; van Praag H
    Arch Gen Psychiatry; 1982 Mar; 39(3):313-9. PubMed ID: 6121545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects.
    Watson SJ; Berger PA; Akil H; Mills MJ; Barchas JD
    Science; 1978 Jul; 201(4350):73-6. PubMed ID: 351804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of naloxone in chronic schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study.
    Silver H; Blacker M; Weller MP; Lerer B
    Biol Psychiatry; 1991 Sep; 30(5):523-5. PubMed ID: 1932400
    [No Abstract]   [Full Text] [Related]  

  • 9. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study.
    Silver H; Nassar A
    Biol Psychiatry; 1992 Apr; 31(7):698-704. PubMed ID: 1599987
    [No Abstract]   [Full Text] [Related]  

  • 10. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
    Kurland AA; McCabe OL; Hanlon TE; Sullivan D
    Am J Psychiatry; 1977 Dec; 134(12):1408-10. PubMed ID: 335903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects.
    Lehmann H; Nair NP; Kline NS
    Am J Psychiatry; 1979 Jun; 136(6):762-6. PubMed ID: 220889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative naloxone effects in schizophrenic patients.
    Janowsky DS; Segal DS; Abrams A; Bloom F; Guillemin R
    Psychopharmacology (Berl); 1977 Aug; 53(3):295-7. PubMed ID: 19807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dosage neuroleptic therapy for acute schizophrenic patients--two double-blind studies with benperidol.
    Nedopil N; Eben E; Klein H; Krüger R; Rüther E; Schmauss M
    Pharmacopsychiatry; 1985 Jan; 18(1):63-6. PubMed ID: 3887439
    [No Abstract]   [Full Text] [Related]  

  • 14. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.
    Grebb JA; Shelton RC; Taylor EH; Bigelow LB
    Biol Psychiatry; 1986 Jun; 21(7):691-4. PubMed ID: 3518822
    [No Abstract]   [Full Text] [Related]  

  • 15. Repeated naloxone administration in schizophrenia: a phase II World Health Organization Study.
    Pickar D; Bunney WE; Douillet P; Sethi BB; Sharma M; Vartanian ME; Lideman RP; Naber D; Leibl K; Yamashita I
    Biol Psychiatry; 1989 Feb; 25(4):440-8. PubMed ID: 2539206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-resistant schizophrenia: controlled study of moderate- and high-dose thiothixene.
    Huang CC; Gerhardstein RP; Kim DY; Hollister L
    Int Clin Psychopharmacol; 1987 Jan; 2(1):69-75. PubMed ID: 3312398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients.
    Naber D; Leibl K
    Pharmacopsychiatria; 1983 Mar; 16(2):43-5. PubMed ID: 6346348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphenylhydantoin effectiveness in the treatment of chronic schizophrenics. A double-blind controlled study with a placebo.
    Simopoulos AM; Pinto A; Uhlenhuth EH; McGee JJ; DeRosa ER
    Arch Gen Psychiatry; 1974 Jan; 30(1):106-11. PubMed ID: 4587066
    [No Abstract]   [Full Text] [Related]  

  • 19. Low dose bromocriptine: a study of acute effects in chronic mediated schizophrenics.
    Cutler NR; Jeste DV; Kaufmann CA; Karoum F; Schran HF; Wyatt RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):277-83. PubMed ID: 6146164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenfluramine and chronic schizophrenia.
    Shore D; Korpi ER; Bigelow LB; Zec RF; Wyatt RJ
    Biol Psychiatry; 1985 Mar; 20(3):349-52. PubMed ID: 3884057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.